ALFA Finder| EBITDA Margin: guided vs achieved | 21.60% achieved Guided 20.00%–22.00% |
|---|---|
| Management target | Revenue 18.0% 2032 |
| Revenue growth | 19.5% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margins expanded 530 bps YoY to 21.6%. |
| Demand visibility | Strong traction in API orders returning after June lag. |
| Management confidence | High; integration complete, balance sheet strongest in history. |
Growth
Revenue grew 19.5% YoY to ₹946 Cr; EBITDA rose 59% to ₹205 Cr. PAT doubled to ₹79 Cr.
Outlook
Guided 18% CAGR to reach $1B by 2032; ₹250-300 Cr annual capex; BioForLife acquisition closing in FY27.
Risks
API volatility due to raw material price fluctuations and ongoing geopolitical conflicts; long gestation for oncology pipeline.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 19.5% (= BEAT)
- Guided ~20% EBITDA margin → delivered 21.6% (= BEAT)
- Guided ₹50-60Cr synergy accrual → delivered ₹60Cr annualized (= BEAT)
Partly delivered
- Guided 26-27% tax rate → delivered 27% (on track = PARTIAL)
- Guided ₹1,000Cr EBITDA target → achieved ₹820Cr annualized run-rate (= PARTIAL)
Investor Presentation filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹255.33
- Market cap
- ₹11,285 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 65.9×Sector 43.8×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.
Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr
Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.
- Value
- ₹3.80 Cr
Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.
Viyash Scientific Capital Structure Change
White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.
Viyash Scientific Other Announcement
Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.